open access

Vol 50, No 2 (2012)
ORIGINAL PAPERS
Published online: 2012-07-05
Submitted: 2012-02-03
Accepted: 2012-02-03
Get Citation

Cytometric evaluation of transferrin receptor 1 (CD71) in childhood acute lymphoblastic leukemia

Anna Płoszyńska, Katarzyna Ruckemann-Dziurdzińska, Agnieszka Jóźwik, Anna Mikosik, Katarzyna Lisowska, Anna Balcerska, Jacek M. Witkowski
DOI: 10.5603/FHC.2012.0040
·
Folia Histochem Cytobiol 2012;50(2):304-311.

open access

Vol 50, No 2 (2012)
ORIGINAL PAPERS
Published online: 2012-07-05
Submitted: 2012-02-03
Accepted: 2012-02-03

Abstract

Transferrin receptor 1 (CD71) is a transmembrane glycoprotein responsible for cellular iron uptake. Higher expression of CD71 has been identified as a negative prognostic marker for numerous solid tumor types and for some lymphomas. The aim of this study was to evaluate CD71 expression on acute lymphoblastic leukemia (ALL) cells and to follow its possible clinical correlations. Sixty one patients, aged 1–17 years and diagnosed with ALL, were enrolled in the study. CD71 expression was analyzed on the bone marrow blastic cells by flow cytometry. CD71 expression on the  eukemic blasts was diversified; in most patients, all blastic cells showed expression of CD71, but levels of expression varied. CD71 expression was statistically higher on T-lineage leukemias. Within the B lineage ALL, a significant difference in CD71 expression existed between precursor B ALL and mature B-ALL, which showed higher CD71 expression. CD71 expression positively correlated with Hgb concentration at diagnosis. Initial risk group assessment and therapy response were not correlated with CD71 expression, although disease free and overall survival times tended to be shorter in patients with B-lineage leukemias with initial high CD71 expression.

Abstract

Transferrin receptor 1 (CD71) is a transmembrane glycoprotein responsible for cellular iron uptake. Higher expression of CD71 has been identified as a negative prognostic marker for numerous solid tumor types and for some lymphomas. The aim of this study was to evaluate CD71 expression on acute lymphoblastic leukemia (ALL) cells and to follow its possible clinical correlations. Sixty one patients, aged 1–17 years and diagnosed with ALL, were enrolled in the study. CD71 expression was analyzed on the bone marrow blastic cells by flow cytometry. CD71 expression on the  eukemic blasts was diversified; in most patients, all blastic cells showed expression of CD71, but levels of expression varied. CD71 expression was statistically higher on T-lineage leukemias. Within the B lineage ALL, a significant difference in CD71 expression existed between precursor B ALL and mature B-ALL, which showed higher CD71 expression. CD71 expression positively correlated with Hgb concentration at diagnosis. Initial risk group assessment and therapy response were not correlated with CD71 expression, although disease free and overall survival times tended to be shorter in patients with B-lineage leukemias with initial high CD71 expression.
Get Citation

Keywords

transferrin receptor 1; CD71; acute lymphoblastic leukemia

About this article
Title

Cytometric evaluation of transferrin receptor 1 (CD71) in childhood acute lymphoblastic leukemia

Journal

Folia Histochemica et Cytobiologica

Issue

Vol 50, No 2 (2012)

Pages

304-311

Published online

2012-07-05

DOI

10.5603/FHC.2012.0040

Bibliographic record

Folia Histochem Cytobiol 2012;50(2):304-311.

Keywords

transferrin receptor 1
CD71
acute lymphoblastic leukemia

Authors

Anna Płoszyńska
Katarzyna Ruckemann-Dziurdzińska
Agnieszka Jóźwik
Anna Mikosik
Katarzyna Lisowska
Anna Balcerska
Jacek M. Witkowski

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl